Results 41 to 50 of about 31,215 (290)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Physiological Approach to the Use of the Natural Compound Quinate in the Control of Sensitive and Resistant Papaver rhoeas

Plants, 2020
Quinate (1,3,4,5-tetrahydroxycyclohexanecarboxylate) is a compound synthesized in plants through a side-branch of the shikimate biosynthesis pathway, which is accumulated after glyphosate and acetolactate synthase inhibiting herbicides (ALS-inhibitors ...
Ana Zabalza, Ainhoa Zulet-González, Maria Barco-Antoñanzas, Mikel V. Eceiza, Miriam Gil-Monreal, Mercedes Royuela   +5 more
doaj   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide [PDF]

, 2001
Background: The sulfonylurea glibenclamide (Glib) abolishes the cardioprotective effect of ischemic preconditioning (IP), presumably by inhibiting mitochondrial KATP channel opening in myocytes. Glimepiride (Glim) is a new sulfonylurea reported to affect
Baxter, G.F., Lawrence, C.L., Maddock, H.L., Mocanu, M.M., Standen, N.B., Yellon, D.M.   +5 more
core  

Glyburide inhibits the Cryopyrin/Nalp3 inflammasome [PDF]

, 2009
Inflammasomes activate caspase-1 for processing and secretion of the cytokines interleukin-1 beta (IL-1 beta) and IL-18. Cryopyrin/NALP3/NLRP3 is an essential component of inflammasomes triggered by microbial ligands, danger-associated molecular patterns
Mohamed Lamkanfi, James L. Mueller, Alberto C. Vitari, Shahram Misaghi, Anna Fedorova, Kurt Deshayes, Wyne P. Lee, Hal M. Hoffman, Vishva M. Dixit, Aguilar-Bryan, Ashcroft, Boyden, Cassel, Clement, Dostert, Duncan, Halle, Hamon, Hoffman, Hornung, Kanneganti, Kanneganti, Laliberte, Lamkanfi, Lamkanfi, Locovei, Ma, Mariathasan, Mariathasan, Martinon, Marty, Meyer, Miki, Miki, Pelegrin, Pelegrin, Perregaux, Riddle, Rosengren, Schott, Solle, Stoller, Sutterwala, Yvan-Charvet   +43 more
core   +2 more sources

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus [PDF]

, 2016
OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability, dosing, drug interactions, and administration of canagliflozin, dapagliflozin, and empagliflozin, and comparing the benefit and risk ...
Ahmed-Sarwar, Nabila, Nathan, Kobi T, Werner, Paul M   +2 more
core   +2 more sources

Sulfonylurea Inadequacy [PDF]

Diabetes Care, 2002
OBJECTIVE—To evaluate the efficacy of the addition of insulin when maximal sulfonylurea therapy is inadequate in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS—Glycemic control, hypoglycemia, and body weight were monitored over 6 years in 826 patients with newly diagnosed type 2 diabetes in 8 of 23 U.K.
Alex Wright, A.C. Felix Burden, Richard B. Paisey, Carole A. Cull, Rury R. Holman   +4 more
openaire   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Diabetes and bone. Focus on DPP-4 inhibitors

Медицинский совет, 2015
Pathology of bone homeostasis in diabetes mellitus (DM) is a significant problem that must be considered when selecting anti-diabetic therapy. Many anti-diabetic drugs have a specific effect on bone homeostasis which should be taken into account when ...
A. Y. Babenko, V. S. Nikitin, T. L. Karonova   +2 more
doaj   +1 more source